Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Merli

Showing results (121-130 of 156) with videos related to

Pageof 16
Sort By:
Annals of Hematology|July 30, 2021
Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana LinfomiArmando Santoro, Rita Mazza, Michele Spina, et al.
American Journal of Hematology|March 4, 2021
Relapsed/Refractory International Prognostic Index (R/R-IPI): An international prognostic calculator for relapsed/refractory diffuse large B-cell lymphomaMatthew J Maurer, Lasse H Jakobsen, Raphael Mwangi, et al.
Hematological Oncology|September 30, 2022
The elderly prognostic index predicts early mortality in older patients with diffuse large B-cell lymphoma. An ad hoc analysis of the elderly project by the Fondazione Italiana LinfomiEmanuele Cencini, Alessandra Tucci, Benedetta Puccini, et al.
Blood Advances|September 18, 2023
Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphomaLoretta J Nastoupil, Georg Hess, Miguel A Pavlovsky, et al.
Hematological Oncology|October 25, 2021
Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real-life experienceFulvio Massaro, Vincenzo Pavone, Piero Maria Stefani, et al.
Haematologica|November 17, 2022
Diffuse large B-cell lymphoma in octogenarians aged 85 and older can benefit from treatment with curative intent: a report on 129 patients prospectively registered in the Elderly Project of the Fondazione Italiana Linfomi (FIL)Alessandra Tucci, Francesco Merli, Alberto Fabbri, et al.
Blood Advances|January 5, 2024
IELSG30 phase 2 trial: intravenous and intrathecal CNS prophylaxis in primary testicular diffuse large B-cell lymphomaAnnarita Conconi, Annalisa Chiappella, Andrés J M Ferreri, et al.
Blood Advances|May 12, 2023
Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCLMaria Chiara Tisi, Riccardo Moia, Caterina Patti, et al.
Infection and Immunity|March 30, 2021
Pharyngeal Microbial Signatures Are Predictive of the Risk of Fungal Pneumonia in Hematologic PatientsClaudio Costantini, Emilia Nunzi, Angelica Spolzino, et al.
Hematological Oncology|May 13, 2025
Comparative Effectiveness of R-miniCOMP Versus R-miniCHOP in Older Non-Fit Patients With Diffuse Large B-Cell Lymphoma: Insights From a "Fondazione Italiana Linfomi" Cohort StudyAlberto Bavieri, Sara Veronica Usai, Michele Merli, et al.
Pageof 16

Showing results (121-130 of 156) with videos related to

Sort By:
Pageof 16
Annals of Hematology|July 30, 2021
Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana LinfomiArmando Santoro, Rita Mazza, Michele Spina, et al.
American Journal of Hematology|March 4, 2021
Relapsed/Refractory International Prognostic Index (R/R-IPI): An international prognostic calculator for relapsed/refractory diffuse large B-cell lymphomaMatthew J Maurer, Lasse H Jakobsen, Raphael Mwangi, et al.
Hematological Oncology|September 30, 2022
The elderly prognostic index predicts early mortality in older patients with diffuse large B-cell lymphoma. An ad hoc analysis of the elderly project by the Fondazione Italiana LinfomiEmanuele Cencini, Alessandra Tucci, Benedetta Puccini, et al.
Blood Advances|September 18, 2023
Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphomaLoretta J Nastoupil, Georg Hess, Miguel A Pavlovsky, et al.
Hematological Oncology|October 25, 2021
Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real-life experienceFulvio Massaro, Vincenzo Pavone, Piero Maria Stefani, et al.
Haematologica|November 17, 2022
Diffuse large B-cell lymphoma in octogenarians aged 85 and older can benefit from treatment with curative intent: a report on 129 patients prospectively registered in the Elderly Project of the Fondazione Italiana Linfomi (FIL)Alessandra Tucci, Francesco Merli, Alberto Fabbri, et al.
Blood Advances|January 5, 2024
IELSG30 phase 2 trial: intravenous and intrathecal CNS prophylaxis in primary testicular diffuse large B-cell lymphomaAnnarita Conconi, Annalisa Chiappella, Andrés J M Ferreri, et al.
Blood Advances|May 12, 2023
Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCLMaria Chiara Tisi, Riccardo Moia, Caterina Patti, et al.
Infection and Immunity|March 30, 2021
Pharyngeal Microbial Signatures Are Predictive of the Risk of Fungal Pneumonia in Hematologic PatientsClaudio Costantini, Emilia Nunzi, Angelica Spolzino, et al.
Hematological Oncology|May 13, 2025
Comparative Effectiveness of R-miniCOMP Versus R-miniCHOP in Older Non-Fit Patients With Diffuse Large B-Cell Lymphoma: Insights From a "Fondazione Italiana Linfomi" Cohort StudyAlberto Bavieri, Sara Veronica Usai, Michele Merli, et al.
Pageof 16